Two evolutionarily conserved purine biosynthesis pathways exist. De novo purine synthesis is an energy-demanding pathway essential for survival in a purine-free environment and embryogenesis. The purine salvage pathway is an energy-efficient process that is favoured in the adult brain 12 and associated with mental disorders and spasticity when deficient 13, 14 . Using patient-derived xenograft (PDX) glioma mice infused with [U-13 C]glucose, we found that glioblastoma (GBM) tissues increase metabolic turnover of GTP ( Fig. 1a and Supplementary Fig. 1a ). Given that GTP is an end product, its high turnover rate may represent the increased metabolic demand. Since infused glucose could be metabolized to salvage metabolites before the uptake by GBM, we took organotypic GBM brain explant assays, which can directly assess glucose metabolism, revealed significant elevation of de novo GTP biosynthesis in GBM tissue. Interestingly, de novo ATP biosynthesis was comparably active in both GBM and normal brain tissues (Fig. 1b) . A full list of affiliations appears at the end of the paper.
In many cancers, high proliferation rates correlate with elevation of rRNA and tRNA levels, and nucleolar hypertrophy. However, the underlying mechanisms linking increased nucleolar transcription and tumorigenesis are only minimally understood. Here we show that IMP dehydrogenase-2 (IMPDH2), the rate-limiting enzyme for de novo guanine nucleotide biosynthesis, is overexpressed in the highly lethal brain cancer glioblastoma. This leads to increased rRNA and tRNA synthesis, stabilization of the nucleolar GTP-binding protein nucleostemin, and enlarged, malformed nucleoli. Pharmacological or genetic inactivation of IMPDH2 in glioblastoma reverses these effects and inhibits cell proliferation, whereas untransformed glia cells are unaffected by similar IMPDH2 perturbations. Impairment of IMPDH2 activity triggers nucleolar stress and growth arrest of glioblastoma cells even in the absence of functional p53. Our results reveal that upregulation of IMPDH2 is a prerequisite for the occurance of aberrant nucleolar function and increased anabolic processes in glioblastoma, which constitutes a primary event in gliomagenesis.
A full list of affiliations appears at the end of the paper. E nlargement and irregular shapes of the nucleolus in tumour cells have been known since at least 1896, but the mechanistic importance to malignancy has remained obscure [1] [2] [3] . In the 1960s, extensive research identified that the nucleolus is the site for ribosomal RNA transcription and assembly [4] [5] [6] . In addition, a clue to more than a epiphenomenal connection between altered nucleolar morphology and malignancy was the notion that the ribonucleic acid (RNA) to deoxyribonucleic acid (DNA) ratio is increased in growing cells and can be an index of overall biosynthetic capacity and cell growth activity from bacteria to humans 7, 8 . RNA is assembled as a chain of four ribonucleotides, ATP, UTP, CTP and GTP, and ribosomal RNA and transfer RNA-both synthesized in the nucleolus 6, 9, 10 -account together for over 90% of all RNA molecules. Interestingly and providing a key insight prompting our mechanistic studies, GTP, but not ATP, concentrations are elevated in several types of tumour 11 , raising the possibility that cells regulate the biosynthesis of ATP and GTP by distinct pathways and that tumours may specifically utilize GTP for processes fundamental to their malignancy. C]glucose for 6 h. H&E, haematoxylin and eosin. b, A murine GBM brain section was treated with [U- 13 C]glucose and subjected to MS imaging analysis. M+6 GTP was detected in organotypic GBM but not in normal brain tissue, while M+6 ATP was detected in both GBM and normal brain tissue. Representative images are shown from two independent experiments. Scale bar, 300 μm. c, The metabolic turnover of GTP is higher than that of the other nucleotides in GBM cells, but not in primary glia. The metabolic turnover rate of the indicated nucleotides is calculated on the basis of the intracellular pool size (middle) and biosynthetic rate (bottom) of ribonucleotides in the indicated cells labelled with [U- 13 C]glucose for 4 h. The data are presented as mean + s.d. n = 3 biologically independent samples. One-way analysis of variance (ANOVA).
Consistent with the results from GBM tissues, in cultured GBM cells, the pool size and the turnover rate of GTP were elevated compared to those of ATP, UTP and CTP ( Fig. 1c and Supplementary  Fig. 1b,c) . In contrast, the turnover rate of GTP in less proliferative primary glia is comparable to those of ATP and CTP and less than that of UTP. Both GBM and primary glia allocate a substantial amount of ATP for biosynthesis of nicotinamide adenine dinucleotide (NAD) and S-adenosylmethionine (SAM) ( Supplementary  Fig. 1d ). Similar results were observed in neural stem cells (NSCs) and the isogenic GBM stem cells (GSCs) that are responsible for therapeutic resistance [15] [16] [17] [18] ( Supplementary Fig. 1e ). Detailed quantification showed that the biosynthetic rate of SAM and NAD + from ATP pathways was more than twofold higher in U87MG and LN229 than in primary glia, consistent with increased growth demand in GBM 19, 20 . We also found that primary glia and NSCs, compared with GBM and GSCs, possess not only more active uptake of purine metabolites from media but also greater active salvage GTP biosynthesis ( Supplementary Fig. 1f-j) . These results suggest that glucose metabolism in GBM is reprogrammed to increase de novo GTP biosynthesis.
upregulation of IMPDH2 in human and murine GBM
To investigate the molecular mechanism underlying the increased GTP biosynthesis in GBM, we analysed gene expression in ten genetically different mouse gliomas ( Fig. 2a and Supplementary  Fig. 2a) . Expression of Impdh2, encoding the enzyme that commits IMP for GTP biosynthesis (Fig. 2b) , displayed the largest increase relative to control brains (about twofold, P < 0.05). In contrast, the expression levels of the isoenzyme encoded by Impdh1, which has indistinguishable substrate affinities and catalytic activities [21] [22] [23] , was minimally affected or even decreased.
Although both the association of increased IMPDH activity with tumours 24 and the anti-tumour activity of IMPDH inhibition have been noted for over 50 years ago [25] [26] [27] [28] [29] [30] , the primary role of IMPDH in promoting tumour growth has remained unclear. To investigate the potential primary role for IMPDH, we first surveyed the expression of IMPDH2 in human GBM patients. Five human GBM databases revealed a more than twofold upregulation of IMPDH2 mRNA ( Supplementary Fig. 2b ). Another key enzyme for de novo GTP biosynthesis, GMPS, was also upregulated and showed a high correlation with IMPDH2 expression levels ( Supplementary Fig. 2b,c) . Interestingly, expression of HPRT1 mRNA, an essential gene for the salvage GTP pathway, was downregulated, while APRT and ADK mRNA, critical genes for the salvage ATP pathway, were reciprocally upregulated showing significant correlation with IMPDH2 levels ( Supplementary Fig. 2b,c) . Immunodetection confirmed overexpressed IMPDH2 in murine glioma, human PDX GBM tissues, established GBM cell lines and GSCs ( Fig. 2c and Supplementary  Fig. 3 ). Four glioma patient cohorts (total 426 specimens) showed a positive correlation of IMPDH2 with increased glioma malignancy (Fig. 2d ) and negative correlation with patient survival (Fig. 2e) . While the mutational status of isocitrate dehydrogenase (IDH) is ;Pten fl/fl mouse brain (lower right). The boxplots follow a Tukey style, in which the lower and upper hinges correspond to the first and third quartiles. The IHC image is a representative one from four independent animals. Scale bar, 1,000 μm. b, A schematic diagram of the purine biosynthesis pathway. c, GBM tissue from the GBM PDX mouse expresses IMPDH2, while IMPDH1 protein was undetectable. n = 1 experiment. d, Analysis of four cohorts showed increased IMPDH2 expression in human glioma specimens with different WHO (World Health Organization) grades (bottom). H&E staining of GBM and representative IHC for IMPDH1 and IMPDH2. The data are presented as mean ± s.e.m. n = 91 for cohort 1; n = 191 for cohort 2; n = 91 for cohort 3; n = 53 for cohort 4. One-way ANOVA. The IHC image is a representative one from cohort 4 (n = 53). Scale bar, 300 μm. e, Kaplan-Meier survival curves for three cohorts of glioma patients based on IDH mutational status (cohort 1 (n = 90); cohort 3 (n = 38)) and the relative strength of cytoplasmic IMPDH2 expression. Cohort 4 (n = 32) is progression-free survival and the others are overall survival. Log-rank tests (two-sided) were used for the statistical analysis. 
one of the most critical biomarkers for molecular classification and patients are in general expected to survive longer [16] [17] [18] 31 , high IMPDH2 expression appeared to confer poor survival even in IDHmutated glioma patients. IMPDH1 levels were marginal in the tested glioma specimens (Fig. 2c,d and Supplementary Fig. 3d-g ). These results indicate that gliomagenesis is associated with upregulation of IMPDH2, but not IMPDH1. In summary, the upregulation of IMPDH2 and its association with systemic changes of genes critical for de novo and salvage GTP synthesis in GBM is consistent with a direct and primary effect of metabolic reprogramming of GTP biosynthesis on GBM. Unpaired two-sided Student's t-test. d, The indicated IMPDH-KO U87MG cells were generated by the CRISPR-Cas9 system as in the Methods. The western blot shows the upregulation of IMPDH1 in IMPDH2-KO U87MG and LN229 cells. Non-specific band is indicated by asterisk. Cells were maintained with 100 μM guanosine-supplemented medium, which was replaced with DMEM/10% dialysed fetal bovine serum (FBS) medium 24 h before the assay. GTP levels were quantified by HPLC. The data are presented as mean + s.d. n = 3 biologically independent samples. One-way ANOVA. Western blot analysis was performed at least twice. e, IMPDH2 KO and IMPDH DKO in U87MG cells decreased the biosynthetic rate of GTP. The assay was performed as in a. The data are presented as mean + s.d. n = 3 biologically independent samples. One-way ANOVA.
IMPDH2 reprograms GTP metabolism in GBM
Next, we assessed the impact of pharmacological and genetic inhibition of IMPDH2. Treatment with mycophenolic acid (MPA), a pan IMPDH inhibitor 23, 32 , dramatically decreased de novo GTP biosynthesis in GBM cells, but not in primary glia (Fig. 3a-c) . GTP biosynthesis was moderately decreased in IMPDH1-knockout (KO) U87MG cells, whereas IMPDH2 KO markedly decreased GTP biosynthesis. Consequently, double KO of both isotypes (DKO) led to a greater decrease in GTP biosynthesis and concentrations (Fig. 3d,e) . The results suggest that upregulation of IMPDH2 reprograms the nucleotide metabolism towards de novo GTP biosynthesis in GBM.
Articles

Nature Cell Biology
IMPDH2 upregulation promotes GBM proliferation in vitro
Although IMPDH2 KO decreased proliferation, the cells were still responsive to MPA, presumably owing to the compensation by IMPDH1 (Fig. 4a) . In support of this notion, IMPDH DKO further decreased cell proliferation and sensitivity to MPA treatment (Fig. 4a , and Supplementary Fig. 4a ). To test this directly, we compared doxycycline-dependent ectopic expression of IMPDH1 or IMPDH2 in IMPDH DKO. Either equivalently rescued cell proliferation (Fig. 4b) . These data suggest that GBM cells compensate for IMPDH2 loss by increasing IMPDH1 and, thus, pan-inhibition of IMPDH would be critical to suppress GBM growth.
Moreover, IMPDH inhibitors, such as MPA, VX-497 33 and mizoribine 34 , decreased the proliferation of all the tested GBM cells and GBM neurospheres, regardless of IDH1 mutational status (Fig. 4c,d and Supplementary Fig. 4b,c) . In contrast, MPA treatment did not affect the proliferation of primary glia. It is noteworthy that the anti-GBM effect of mizoribine, a pro-drug requiring phosphorylation by adenosine kinase 34 , required a much higher concentration than MPA and those observed in the other types of cancer 28 , presumably due to the differential drug metabolism in glioma.
The effect of IMPDH inhibitors was abrogated by high exogenous guanosine concentrations above 10 μM, two orders of magnitude higher than normal blood or cerebrospinal fluid concentrations 35, 36 .
To assess the contribution of the salvage pathway to cell proliferation, we generated HPRT1-deficient GBM cells. The HPRT1-KO U87MG, LN229 and A172 cells were completely resistant to 6-thioguanine, while a high concentration of 6-thioguanine suppressed the growth of the parental cells, indicating that these cells have residual HPRT1 activity ( Supplementary Fig. 4d ). However, the proliferation rate of HPRT1-KO U87MG, LN229 and A172 cells was comparable to that of their parental cells ( Supplementary Fig. 4d ), suggesting that the salvage GTP biosynthesis is dispensable for GBM cells, in contrast to the de novo GTP biosynthesis. Interestingly, in line with the restriction in salvage GTP biosynthesis in vitro ( Supplementary  Fig. 1j ), guanosine rescue worked marginally for GSCs in a culture dish and brain explant (Fig. 4c ,e and Supplementary Fig. 5a ), implying a potential metabolic vulnerability of GSCs.
IMPDH requirement of in vivo GBM growth and malignancy
In accordance with the in vitro and ex vivo analyses, pharmacological inhibition of IMPDH suppressed tumour formation and progression of subcutaneously xenografted U87MG cells ( Fig. 4f and Supplementary Fig. 5b ). IMPDH2-KO U87MG cells displayed severely decreased tumorigenic activity and IMPDH DKO failed to form tumours ( Fig. 4g and Supplementary Fig. 5c ). However, in an orthotopic GBM model, IMPDH2-KO U87MG could form tumours that grow even faster than parental U87MG cells ( Supplementary  Fig. 5d ). Subsequently, we observed significant upregulation of IMPDH1 in IMPDH2-KO U87MG, suggesting a mechanism explaining the tumour growth ( Supplementary Fig. 5d ). In contrast, IMPDH DKO significantly impaired tumour growth in the brain (Fig. 4h) , corroborating the compensatory expression of IMPDH1 following IMPDH2 depletion. Taken together, these results reveal the essential role of IMPDH activity in the maintenance and proliferation of GBM cells in vivo.
IMPDH2-mediated GTP biosynthesis fuels rRNA and tRNA synthesis
The primary metabolic fates of GTP are degradation to uric acid, deoxygenation to dGTP for DNA synthesis, or substrate for RNA synthesis (Fig. 5a ). In GBM, we found that GTP is rapidly turned over in contrast to other ribonucleotides ( Fig. 1c and Supplementary  Fig. 1c ). Inhibition of the IMPDH pathway acutely depleted GTP, despite nearly 80% of the cells being in a non-S-phase (Fig. 3a-c and Supplementary Fig. 6a,b) . Using [U- 13 C]glucose flux analysis, 13 C-labelled dGTP and uric acid-a catabolic product of GTP-were almost undetectable ( Supplementary Fig. 6c ). This suggests that the IMPDH-pathway-derived GTP is used in some process(es) other than DNA synthesis or catabolism in the GBM cells. Importantly, treatment with specific inhibitors of rRNA synthesis-CX-5461 37 and BMH-21 38 -completely blocked the MPA-induced decrease of GTP, indicating that RNA polymerase I (Pol I)-dependent transcription drives GTP consumption ( Fig. 5b and Supplementary Fig. 6d ).
To extend this observation, we established a tracking method for the metabolic fate of ribonucleotides termed stable-isotope measure of influxed ribonucleic acid index (SI-MOIRAI) ( Supplementary  Fig. 6e ). The SI-MOIRAI is a combination of the [U- 13 C]glucose flux assay and mass spectrometry (MS), enabling quantification of the newly synthesized ATP, UTP, GTP, CTP into RNA under steadystate conditions. Strikingly, our SI-MOIRAI-based steady-state analysis showed that the utilization rate of 13 C-labelled GTP is twofold higher than that of ATP in rRNA and tRNA, but not in mRNA (Fig. 5c ). Furthermore, 13 C-labelled pyrimidine nucleotides exhibited a significantly lower utilization rate (Fig. 5c ). These results suggest that GBM cells require IMPDH2-dependent GTP biosynthesis to support primarily rRNA and tRNA synthesis, whereas mRNA synthesis is not dependent on this change in nucleotide metabolism.
IMPDH2-mediated GTP biosynthesis is required for Pol I and Pol III transcription
Many tumour cells increase Pol I activity 6, 10, 39 and GTP-dependent Pol I activation has been shown in several types of tumour [40] [41] [42] . One-way ANOVA. n = 1 experiment for western blot analysis. c, MPA treatment suppresses cell proliferation in GBM, but not primary glia. The data are shown as an average of two biologically independent samples. d, MPA treatment suppresses IDH1-mutated GSC proliferation. The data are presented as mean + s.d. n = 3 biologically independent samples. One-way ANOVA. e, Growth of murine GSCs in brain tissue is inhibited by MPA. GFP-expressing murine GSC brain explant slices in immunocompetent mice were cultured with or without 10 μΜ MPA and 100 μM guanosine. Scale bars, 300 μm. n = 1 experiment. Similar MPA responses were confirmed in Supplementary Fig. 5a . f, A clinically used IMPDH inhibitor (mycophenolate mofetil, MMF 23, 27, 32 ) suppresses GBM growth in vivo. MMF was orally administrated (120 mg kg 
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Consistent with these previous studies, Pol I activity is upregulated in U87MG compared to primary glia ( Supplementary Fig. 7a ). Furthermore, we found an additional link between GTP and nucleolar transcription in GBM. When cellular GTP concentrations decreased to below 200 μM, pre-rRNA (Pol I transcript) and pre-tRNAl13 (Pol III transcript) expression levels in GBM cells were diminished, while pre-GAPDH mRNA (Pol II transcript) was unaffected (Fig. 6a,b) . Mature tRNAs were also downregulated ( Fig. 6c and Supplementary Fig. 7b ), suggesting stress-dependent tRNA cleavage 43 . Indeed, under conditions of low Pol I and III transcription, MPA treatment triggered the nucleolar stress response 44, 45 (that is, delocalization of nucleolin, induction of the p53 pathway and degradation of nucleostemin, a nucleolar marker of stem and cancer cells whose stability requires GTP binding (Fig. 6d,e and Supplementary  Fig. 7c-f) ). However, no gross changes in the levels of PI(3)K, mTOR and ERK/RSK signalling were detected (Fig. 6f) .
Chromatin immunoprecipitation (ChIP) analyses revealed that, whereas gene occupancy of the architectural factor UBF was unaffected by MPA regardless of the cell line, MPA treatment decreased promoter and gene body binding of Pol I in U87MG and A172, but not in LN229 cells (Fig. 6g,h ). MPA-treated U87MG and A172 cells, that are both p53 wild type, respond with p53-mediated inhibition of Pol I transcription initiation 46 , whereas in p53-mutated LN229 cells, elongation is blocked, leading to stalling of Pol I. In line with this notion, a Pol I minigene assay showed severely impaired transcription initiation in response to MPA in U87MG cells, but not in LN229 cells (Supplementary Fig. 7g ). These data show that inhibition of IMPDH represses rRNA synthesis and induces nucleolar stress, even in GBM cells lacking functional p53.
IMPDH2 upregulation is critical for nucleolar transformation in GBM
Next, we performed two-dimensional transcriptome screening for IMPDH2-dependent gene expression networks (Fig. 7a) . In the first dimension, we set out to identify genes regulated by IMPDH activity. We analysed the transcriptome of U87MG cells and C-labelled nucleosides to total nucleosides in the indicated RNA species is shown as a percentile (right). n = 2 biologically independent samples for r/tRNA; n = 1 sample for mRNA. ND, not detectable.
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Nature Cell Biology accepted model is that IMPDH inhibition suppresses DNA synthesis and mitotic progression of T cells that enter S-phase 51 . However, IMPDH inhibition causes cell-cycle arrest at G1-phase in many tumours, and the progression to S-phase and the following mitotic suppression under GTP-depletion depends on cell type or cellular context (for example, mutation TSC2) 28 . In the present study, using a newly developed and previously unavailable method, SI-MOIRAI, which overcomes the issue of the pleiotropic effect caused by GTP depletion, we have unveiled the metabolic fate of newly synthesized GTP to rRNA and tRNA. The results of SI-MOIRAI explain why inhibition of Pol I activity, by two Pol I inhibitors, completely suppressed the MPA-dependent GTP depletion ( Fig. 5b and Supplementary Fig. 6d ). Decreased GTP concentration by MPA treatment suppresses both Pol I and Pol III transcription, while Pol II transcription is unaffected. Taken together, our studies provide direct evidence elucidating the primary role of IMPDH2 in providing metabolic substrates supporting de novo-synthesized GTP to nucleolar rRNA and tRNA synthesis in GBM.
The results also highlight the qualitative differences in rRNA synthesis between GBM and primary glia. In GBM cells, Pol I transcription requires IMPDH2-dependent de novo GTP biosynthesis, while primary glia use the salvage pathway for sustaining Pol I transcription. All differentiated, less proliferative or quiescent cells, such as primary glia, have a nucleolus and continuously produce ribosomes. This observation has at least two major implications: it provides insight into how metabolically inactive cells maintain ribosome biogenesis (one of the most anabolic cellular processes), and it highlights the therapeutic potential of the IMPDH pathway to suppress ribosome biogenesis in tumour cells but not in normal tissue.
Our study raises a number of important questions. The mechanism of IMPDH2 upregulation in GBM is of particular basic importance. Previous reports show that cMyc increases IMPDH1 and IMPDH2 29, 30, 52 . However, cMyc itself may not explain the rather selective upregulation of IMPDH2 in GBM; therefore, there are probably additional levels of regulation for IMPDH2 upregulation. Other questions include the identity of the mechanism regulating GTP-dependent Pol I and Pol III transcription, whether nucleolar enlargement is a passive structural manifestation, whether the nucleolar changes have an active role in directly promoting tumour growth, and whether existing or more selective IMPDH inhibitors could benefit and prolong GBM patients' survival while minimizing their strong immunosuppressive effects and other toxicities 32, 53, 54 ? Further studies on understanding tumour-specific regulation of IMPDH2 coupled with improved design of currently available identified 3,675 genes whose expression levels were downregulated after IMPDH inhibition. Interestingly, although the IMPDH inhibition showed a negligible effect on ribosomal protein coding genes (Fig. 7b) , a significant change was observed in a subset of nucleolar localizing proteins, including ribosome processing factors, and nucleolar architecture regulators (Fig. 7a) . In the second dimension, we sought genes correlated with IMPDH2 expression. We extracted 721 genes whose expression levels are correlated with IMPDH2 mRNA expression from the transcriptome of GBM patients. A total of 356 genes are overlapped with the IMPDH-associated down regulated genes (Fig. 7a) . The 61 genes that correlated with IMPDH2 expression in GBM patients as well as responded to MPA treatment in U87MG cells are implicated in nucleolar function and morphology (Fig. 7a) .
Remarkably, pharmacological inhibition of IMPDH2 activity led to decreased nucleolar density and size, and more rounded, ring-shape nucleoli as compared to the control cells. Guanosine supplementation and ectopic expression of IMPDH2 reverted the phenotype back to enlarged and irregular-shaped nucleoli (Fig. 7c,d and Supplementary Fig. 7h,i) . Furthermore, the nucleolar size in IMPDH2-KO U87MG tumour specimens was significantly decreased compared to wild-type U87MG tumours in vivo ( Supplementary Fig. 7j ) and ex vivo ( Supplementary Fig. 7k ). In human glioma patient specimens, IMPDH2 expression was significantly correlated with nucleolar enlargement in the grade II and grade III gliomas (Fig. 7e) . Together, these data suggest that IMPDH-mediated GTP production directly contributes to the formation of enlarged, irregular nucleoli in GBM cells.
Discussion
Increased rRNA synthesis 47 and nucleolar hypertrophy 1,2 have both long been recognized as features of malignant transformation. Our data, by revealing that upregulation of IMPDH2 in GBM cells drives de novo GTP biosynthesis, enhances rRNA and tRNA synthesis and stimulates nucleolar hypertrophy, connect these two long observed features of cancer (Fig. 7f) .
Our primary result establishing a mechanistic connection between GTP metabolism, IMPDH2, nucleolar hypertrophy and malignancy prompts a reappraisal of the published literature on IMPDH. The anti-tumour effect of IMPDH inhibitors has been known for over 50 years 25, 26 , but the primary effect of IMPDH inhibition on tumour cell growth has been poorly understood. There are contradictory models 27 including integrin dysfunction, caspase-3 activation, PPARγ-mediated differentiation, and decreased signalling of Ras/ERK 48, 49 and mTOR 50 . The most widely 
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Any methods, additional references, Nature Research reporting summaries, source data, statements of code and data availability and associated accession codes are available at https://doi.org/10.1038/ s41556-019-0363-9. Cell culture. U87MG (ATCC line), LN229, U251 and A172 cells were cultured in Dulbecco's modified Eagle medium (DMEM) containing 10% FBS. GBM patient-derived neurospheres and GSCs were isolated and cultured as previously described [56] [57] [58] [59] . For primary glia isolation, the cerebral cortex from newborn mice (2 or 3 d old) was collected and homogenized with Leibovitz's L-15 medium. After washing with PBS, homogenates were treated with DNase and trypsin. Cells were cultured in minimum essential medium (MEM/EBSS, GE Healthcare) containing 10% horse serum (HS). Medium was changed every 3 d. Human astrocytes (ScienCell Research Laboratories, no. 1800) were maintained in Astrocyte medium (no. 1801), which enriches growth factors enabling high proliferation, and habituated in MEM/EBSS/10% HS for two weeks before the assay.
Analysis of gene expression in RCAS/tv-a murine GBM models.
Using the Gene Expression Omnibus (GEO; accession number GSE45874), which harbours a total of 72 murine samples produced by the RCAS/tv-a system 60 , we extracted signal intensity data of the Illumina BeadChip after normalization by the lumi R package. With a knowledge-based search about gene symbols and ids, we obtained 28 probes of 17 genes annotated as a gene in the purine synthetic pathway after manual curation (Supplementary Table 8 ). We applied the prcomp R package for principal component analysis. To detect the genes that were differentially expressed between normal and tumour samples, we used the P values calculated by the Wilcoxon rank sum test implemented in R (Wilcox.test) after Bonferroni correction. IMPDH protein quantification by western blot analysis. For the quantification of IMPDH amounts, His-tagged recombinant human IMPDH proteins were purified in Escherichia coli using Talon Metal Affinity Resin (Clontech). These proteins were subjected to western blot analysis together with cell lysates and cellular IMPDH amounts were calculated by the standard curves. To calculate the concentration, cell numbers were counted and cell volumes were measured using Packed Cell Volume tubes (Techno Plastic Products).
Virus production and transduction. Human wild-type IMPDH1 and IMPDH2 cDNA were cloned into the pLenti CMV Hygro DEST vector (Addgene, no. 17454), and the virus was produced by co-transfection of pMD2.G (Addgene, no. 12259) and psPAX2 (Addgene, no. 12260) into HEK293T. For transduction, 1 × 10 5 cells per 12-well plate were treated with virus-containing media and 8 μg ml Polybrene, and centrifuged at 1,200g for 20 min. The medium was replaced with the appropriate fresh medium the next day. Cells were selected with hygromycin B for at least one week.
Nucleotide measurement by HPLC. Nucleotide measurement was performed as described previously with some modifications 61 . To calculate the concentration, cell numbers were counted and cell volumes were measured using Packed Cell Volume tubes.
Metabolome analysis. All stable isotopes were purchased from Cambridge Isotope Laboratories, Inc. Cells were seeded on a 100 mm dish and cultured overnight. The next day, culture media were replaced with [U- [U- N 2 -glutamine was used. Cells were collected at the indicated times. Extraction of metabolites was performed as previously described 62 . CE timeof-flight MS (CE-TOFMS) experiments were performed using an Agilent G7100A CE instrument (Agilent Technologies), an Agilent 6224 TOF LC/MS system (Agilent Technologies), an Agilent 1200 series isocratic HPLC pump, a G1603A Agilent CE-MS adapter kit and a G1607A Agilent CE-electrospray ionization-MS sprayer kit. For CE-TOFMS system control and data acquisition, we used Agilent MassHunter software. Detailed conditions for CE-TOFMS-based metabolome analysis were described previously 63, 64 . Capillary ion chromatography (IC)-MS analysis was performed using a Dionex ICS-5000 + system equipped with a Q Exactive Orbitrap MS system (Thermo Fisher Scientific).
Cell proliferation analysis.
To measure cell proliferation, relative cell numbers were measured using crystal violet staining for adherent cells. Cells were fixed with 4% paraformaldehyde in PBS, stained with 0.04% crystal violet aqueous solution for 15 min and dissolved in 1% SDS. The absorbance was measured at 595 nm. For GSCs, cells were assayed using the CellTiter 96 Aqueous One Solution Cell Proliferation assay (MTS) (Promega) according to the manufacturer's instructions.
Establishment of IMPDH-KO cells the by CRISPR-Cas9 system and mouse IMPDH-expressing cells. For CRISPR-Cas9-mediated gene KO, gRNAs were designed by the CRISPR design program (http://crispr.mit.edu/) (GTGTCGTCGGGTGTGTAGCG for IMPDH1, ACATCCCGCACGCGATCCTT or GATACCGCAGAAACCATGCC for IMPDH2, TCTTGCTCGAGATGTGATGA for HPRT1). gRNAs were subcloned into lentiCRISPRv2 (Addgene plasmid no. 52961). U87MG, LN229 and A172 cells were transduced with the lentivirus and selected by puromycin. To avoid compensatory responses, IMPDH-KO cells were cultured with 100 μM guanosine. Single clones of IMPDH2-and IMPDH-DKO U87MG cells were isolated by FACSAria sorting (BD Biosciences). To establish doxycycline-inducible gene-expressing cells, cDNA fragments of mImpdh1, 2 were subcloned into pTRIPZ (GE Healthcare). Transduced cells were treated with 1 μg ml −1 doxycycline for ectopic gene expression.
Xenograft assay. A total of 2.5 × 10 6 cells were subcutaneously injected into athymic Nude-Foxn1 nu homozygous mice (Harlan) around 8 weeks of age with Matrigel (Corning). Tumour volumes were measured twice a week and calculated using the equation D´d´d´π=6 I (D = larger diameter, d = smaller diameter). For MMF treatment, mice were treated with MMF by oral gavage from the next day of injection. For the delayed treatment, mice were treated with MMF by oral gavage after the tumour size reached 200 mm 3 . MMF was dissolved in 0.5% methylcellulose/0.1% Tween 80 solution and 120 mg kg −1 amounts were administrated orally. A 0.5% methylcellulose/0.1% Tween 80 solution was used for vehicle treatment. When mice did not form tumours, those data were excluded from the statistical analysis. All of the animal experiments in this study are compliant with all relevant ethical regulations regarding animal research.
Orthotopic implantation. Implantation of cells into the brains of female athymic Nude-Foxn1
nu homozygous mice (for U87MG/GFP-luciferase cells) and C57BL/6J mice (for GSCs) was performed as described previously 56 . A Carestream (Kodak) MultiSpectral FX (two-dimensional) system was used to visualize tumours for U87MG cells after intravenous injection of Luciferin (Gold Biotechnology). For the metabolite quantification experiments, 2 × 10 6 viable GFP-NSCs were implanted contralaterally. All animal experiments were approved by the Animal Care and Use Committees of University of Cincinnati, Keio University and Hiroshima University.
Ex vivo GBM analysis. For metabolite quantification experiments, brains were removed 5 d after implantation and 200 µm coronal slices were prepared with the use of a LeicaVS1200 vibratome (Leica). Explants were placed on Millicell-CM culture inserts (Merck Millipore) in glass-bottom plates, and allowed to recover for 1 h in NSM at 37 °C under a humidified atmosphere of 5% CO 2 (ref. 65 ). Images of the slices were acquired with a Fluoview FV10i inverted confocal microscope (Olympus), after which the explants were switched to either fresh NSM or glucosefree NSM supplemented with [U- . After a 3 h incubation, explants were frozen and stored at −80 °C until analysis. For drug treatment experiments, 150 µm explants were prepared 8 d after implantation, allowed to stabilize for 1 h and then switched to fresh NSM or NSM containing 10 µM MPA, 10 µM MPA and 1 µM guanosine or 10 µM MPA and 10 µM guanosine. Medium with or without drugs was replenished daily. At the end of the study, slices were fixed overnight with 4% paraformaldehyde, embedded in paraffin and sectioned at a thickness of 3 μm.
Matrix-assisted laser desorption/ionization-MS imaging acquisition. Matrixassisted laser desorption/ionization (MALDI) imaging analyses were performed as described previously 66, 67 . Briefly, thin sections (8 µm) of the brain were prepared with a cryomicrotome (CM3050, Leica). Sections were attached onto indium tin oxide-coated glass slides (Bruker Daltonics) and were coated with 9-aminoacridine as the matrix (10 mg ml −1 , dissolved in 80% ethanol) by manually spraying with an artistic-brush (Mr. Hobby). The matrix was simultaneously applied to multiple sections being compared to maintain consistent analyte extraction and cocrystallization conditions. MALDI imaging was performed using an Ultraflextreme MALDI-TOF/TOF mass spectrometer equipped with a Nd:YAG laser and a linear ion-trap MS with a MALDI source (MALDI LTQ XL, Thermo Fisher Scientific) equipped with a nitrogen laser (337 nm; 60 Hz). Data were acquired in the negative reflectron mode with raster scanning at a pitch distance of 50 µm. For the TOF/ TOF measurement, signals between m/z 50 and 1,000 were collected and image reconstruction for both procedures was performed using FlexImaging 4.1 software (Bruker Daltonics). For the ion-trap instrument, the obtained spectral data were Immunohistochemistry. After being deparaffinized, sections were pretreated in Cell Conditioning Solution (CC2) (Roche) for 44 min at 91 °C, and then incubated with anti-IMPDH2 antibody (1:100 or 200) and anti-IMPDH1 antibody (1:100) for 32 min at room temperature. After incubation, signals were detected using the UltraView DAB detection kit (Roche). For counterstaining, slides were treated in haematoxylin for 4 min and bluing reagent (Roche) for 4 min. These processes were run on the BenchMark ULTRA (Roche). Human brain glioma tissue arrays were obtained from three independent institutes (anonymous for blind review) and US Biomax (BS17016a, NGL961, GL482). IMPDH1 and IMPDH2 immunostaining intensity was scored by board-certified pathologists on a semiquantitative scale from 0 (negative) to 3 (strong). In the figures, the low-expression group corresponds to the scale 0 and 1, and the high-expression group corresponds to the scale 2 and 3.
Microarray. U87MG cells were treated with 10 μM MPA or 100 μM guanosine for 24 h, and then RNA was extracted with ISOGEN (Nippon Gene). The Genechip Primeview Target Synthesis and Labeling Assay was used to create biotin-labelled target cDNA. Samples were subjected to Affymetrix Genechip Primeview Human Gene Expression Array. The microarray data were deposited in the GEO (GSE124727).
IMPDH2 network analysis.
By comparison of the signal strengths between MPAtreated and control U87MG microarray data, downregulated genes were extracted as the genes affected by the inhibition of IMPDH activity. Gene expression profiles of 10,133 genes with a single replicate were applied to the analyses. For GO analyses, P values obtained by Fisher's exact test (one-sided) using topGO were shown without any adjustment. For the significance of overlaps, P values obtained by a hypergeometric test after Bonferroni multiple correction were shown as q values. A value of <1 × 10 −30 was used as the minimum value in the output of the R topGO library due to the underflow problem. P values for the probability of overlaps (shown as q value <1 × 10 −5 in Fig. 7 ) also contain the zero P values due to the underflow problem. To avoid an inappropriate description, we placed caps of 1 × 10 −5 on q values, which at least can be computed precisely. The candidates for IMPDH2-correlated and nucleolar localized genes were obtained from The Cancer Genome Atlas GBM data via GlioVis 68 and the nucleolar proteome data 69 , respectively. The overlapped genes between each gene list were extracted for GO enrichment analysis using topGO (Bioconductor, R package version 2.32.0) and P value computation by hypergeometric test.
ChIP. After formaldehyde-fixation (0.25% formaldehyde, 10 min at room temperature) and quenching with 125 mM glycine (5 min), cells were collected in PBS and nuclei were prepared by successive incubation in buffer A (100 mM Tris-HCl (pH 8.1), 10 mM dithiothreitol), buffer B (10 mM HEPES (pH 7.5), 10 mM EDTA, 0.05 mM EGTA, 0.25% Triton X-100) and buffer C (10 mM HEPES (pH 7.5), 10 mM EDTA, 0.05 mM EGTA, 200 mM NaCl). Nuclei were disrupted in buffer D (50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 1% SDS) and chromatin was sonicated in a Bioruptor Pico (Diagenode) to an average length of 200-500 bp. Chromatin was diluted with 5 volumes of ChIP buffer (15 mM Tris-HCl (pH 8.0), 180 mM NaCl, 1.2 mM EDTA, 1.2% Triton X-100) and pre-cleared for 1 h at 4 °C on Protein A/G-Sepharose (GE Healthcare) that had been blocked with 1 mg ml −1 BSA and 1% gelatin from cold-water fish skin (Sigma-Aldrich). Per ChIP reaction, approximately 20 µg chromatin was incubated with 1 to 2 µl of polyclonal antisera overnight at 4 °C followed by incubation with Protein A/G-Sepharose for 1 h. Immobilized complexes were washed two times in low-salt buffer (20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton X-100), high-salt buffer (20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton X-100), LiCl buffer (10 mM Tris-HCl (pH 8.0), 250 mM LiCl, 1 mM EDTA, 1% sodium deoxycholate, 1% NP-40) and TE buffer. DNA was eluted from the beads by incubation in 100 µl of 0.1 M NaHCO3/1% SDS for 10 min at room temperature. The crosslink was reversed by heating at 65 °C for 6 h and the DNA was purified using the ChIP DNA clean and concentrator kit (Zymo Research). Purified DNA was analysed by qPCR (see Supplementary Table 10 for primer sets).
Real-time PCR analysis. Total RNAs were extracted using TRI REAGENT (Molecular Research Center) or TriFast Reagent (Peqlab) according to the manufacturer's instructions. The High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific) or SuperScript IV Reverse Transcriptase (Life Technologies) was used to prepare the cDNA solution. For real-time PCR analyses, Maxima SYBR Green/ROX qPCR Master Mix (2×) (Thermo Fisher Scientific) was used according to the manufacturer's instructions. Reactions were performed using the pre-set program of the ABI 7500 Fast Real-Time PCR system (Thermo Fisher Scientific). For Pol I reporter gene assays, cells were transfected with plasmid pHrP2-BH, which harbours an artificial ribosomal minigene containing a 5′-terminal human rDNA fragment (from −411 to −375) and two rDNA terminator elements. After RNA isolation and cDNA synthesis, the reporter gene was detected with forward and reverse primers matching rDNA and plasmid sequences, respectively. All primers used are shown in Supplementary Table 10 .
Immunofluorescence and nascent RNA analysis. Cells grown on coverslips were fixed with 1% paraformaldehyde for 5 min, permeabilized with 0.5% Triton X-100 for 5 min and incubated with primary antibodies overnight at 4 °C. For labelling of nascent RNA, cells were pulse-labelled with 2 mM 5-fluoro-uridine (FUrd) for 20 min before fixation. Nucleolar proteins were immunostained with the indicated antibodies and labelled RNA was detected with anti-BrdU antibodies. After incubation overnight at 4 °C and washing with PBS, appropriate secondary antibodies coupled to fluorophores were added for 45 min at room temperature. Coverslips were stained with Hoechst 33342 to visualize nuclear DNA, and then mounted, and pictures were taken with a Nikon fluorescence microscope and digitally recorded.
Tissue microarray. The human glioma tissue array was constructed at the University of Kentucky, the University of California Los Angeles and Osaka City University, with written informed consent. The experimental protocol was approved by the Institutional Review Board of each institute. We also purchased commercially available human glioma tissue arrays from US Biomax, Inc. (BS17016a, NGL961 and GL482). The study is compliant with all relevant ethical regulations regarding research involving human participants.
PDX model. Preparation of PDX models and infusion of [U-
13 C]glucose were performed as described previously 70 . Human orthotopic tumour samples were obtained from patients at the University of Texas Southwestern Medical Center after written informed consent and Massachusetts General Hospital under a protocol approved by the Institutional Review Boards. The study is compliant with all relevant ethical regulations regarding research involving human participants.
SI-MOIRAI.
Total RNAs were extracted using the miRNeasy kit (QIAGEN) and electrophoresed by a 0.8% native agarose gel for 40 min with 100 V in TBE buffer with single-stranded RNA ladder and low-range single-stranded RNA ladder RNA size markers (Bio-Rad). RNAs (mRNA (>10,000 nucleotides), 28S rRNA, 18S rRNA and tRNA) were excised with a razor blade, and extracted from the gel using the NucleoSpin Gel and PCR Clean-up Kit (MACHEREY-NAGEL). RNA (20 µl) was heated (92 °C for 5 min), and then chilled in an ice-water slush. For digestion, the RNA samples were treated with 1 µl of Antarctic phosphatase buffer (pH 7.0, New England BioLabs) and 1 µl (2 units) of nuclease P1 (Sigma), for 3 h at 50 °C. Then, the samples were treated with 1 µl (0.2 units) of venom phosphodiesterase (Worthington Biochemical) for 2 h at 37 °C, following treatment with 10 µl (0. Electron microscopy. Specimens were immersed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (100 ml; pH 7.4) for 2 h at 4 °C. Specimens were then treated with 1% OsO4 for 2 h at 4 °C, and then with saturated uranyl acetate for 3 h at room temperature. Thereafter, specimens were dehydrated in a graded series of ethanol and embedded in epoxy resin. Ultrathin sections (70 nm thick) were prepared, counterstained with saturated uranyl acetate followed by lead citrate, and observed using a JEM-1400Plus electron microscope (JEOL).
Nucleolus morphology. Cells were cultured as indicated, and then pictures were taken. At least ten cells were assessed by ImageJ software (National Institutes of Health). For methyl green pyronin staining, sections were rinsed in pH 4.8 buffer (acetic acid: 0.08 M, sodium acetate: 0.12 M) and incubated for 60 min in methyl green pyronin solution (0.2% methyl green, 0.2% pyronin Y). Sections were again rinsed in pH 4.8 buffer, and then dehydrated and mounted. After histological evaluation and taking pictures, at least 20 nucleoli were assessed by ImageJ.
Statistics and reproducibility. The statistical analyses were performed using the unpaired two-sided Student's t-test, one-way ANOVA and the Mann-Whitney test using Microsoft Excel and GraphPad Prism 6 or 7 (GraphPad Software). ANOVA was used to compare more than two groups. Data were considered statistically significant at *P < 0.05, **P < 0.01. No statistical method was used to determine sample size. The experiments were repeated independently with similar results. For Fig. 1a , a tumour sample was split into two and analysed by IC-MS in two institutes, showing similar results. For the flux analyses, nucleotide measurements by HPLC, cell proliferation assays and animal experiments, biologically independent samples were used, showing similar results. For the SI-MOIRAI experiment (Fig. 6c) , one of the data sets from duplicates is shown. For Fig. 7c , the electron microscope analysis was performed once but similar results were obtained under a light microscope.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
nature research | reporting summary
October 2018
Corresponding author(s): Atsuo T. Sasaki Last updated by author(s): Mar 28, 2019 Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Software and code
Policy information about availability of computer code Data collection Affemetrix Genechip Command Console software (Thermo Fisher Scientific) was used for scanning GeneChips.
Data analysis
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